Nicholas Palladino, MD
Internal Medicine · Sicklerville, NJNPI 1639116569
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $51,483 of the $61,658 with a category attached, or 83.5%. Avanir Pharmaceuticals, Inc. accounts for 95.8% of it on its own, with 34 other manufacturers making up the rest. Reporting peaked in 2019 at $28,680 and has fallen 97.5% since, to $726 in 2025. Among internal medicine clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 198 payments — averaging $311.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Avanir Pharmaceuticals, Inc.$59K
- Otsuka America Pharmaceutical, Inc.$671
- AstraZeneca$166
- Astellas Pharma US Inc$151
- Teva Pharmaceuticals USA, Inc.$149
- Bayer$134
- plus $1K from 29 others
What the payments were for
- Consulting fees$2,2404%
- Speaking & faculty fees$51,48383%
- Travel & lodging$2,7184%
- Food & beverage$5,1178%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Avanir Pharmaceuticals, Inc. | 85 | $59,088 |
| Otsuka America Pharmaceutical, Inc. | 20 | $671 |
| AstraZeneca | 4 | $166 |
| Astellas Pharma US Inc | 6 | $151 |
| Teva Pharmaceuticals USA, Inc. | 3 | $149 |
| Bayer | 7 | $134 |
| Neurocrine Biosciences, Inc. | 1 | $125 |
| Eisai Inc. | 8 | $120 |
| Abiomed | 1 | $109 |
| GSK | 7 | $104 |
| Amarin Pharma, Inc. | 6 | $83 |
| Novartis | 5 | $82 |
| Sumitomo Pharma America, Inc. | 6 | $79 |
| Pfizer | 5 | $64 |
| Acadia Pharmaceuticals Inc | 4 | $62 |
| Sunovion Pharmaceuticals Inc. | 4 | $56 |
| Vanda Pharmaceuticals Inc. | 2 | $38 |
| Abbott | 2 | $37 |
| Novo Nordisk | 3 | $36 |
| Neotract Inc. | 1 | $33 |
| Boston Scientific | 1 | $29 |
| Kyowa Kirin, Inc. | 2 | $29 |
| Lilly USA, LLC | 2 | $26 |
| Sanofi Pasteur Inc. | 1 | $25 |
| AbbVie | 2 | $23 |
| Lundbeck LLC | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Urovant Sciences Inc | 1 | $14 |
| Sun Pharmaceutical Industries Inc. | 1 | $13 |
| Merck | 1 | $13 |
| Philips North America LLC | 1 | $13 |
| Amgen | 1 | $13 |
| Johnson & Johnson | 1 | $12 |
| Shire North American Group Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$61,658 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,429 | $533,715 |
| XareltoRivaroxaban | 273 | $116,293 |
| JanuviaSitagliptin Phosphate | 191 | $80,281 |
| Dimethyl Fumarate | 20 | $51,476 |
| Atorvastatin Calcium | 2,240 | $36,718 |
| JardianceEmpagliflozin | 99 | $35,159 |
| Breo ElliptaFluticasone/Vilanterol | 82 | $34,962 |
| EntrestoSacubitril/Valsartan | 82 | $33,960 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $27,770 |
| Potassium Chloride | 949 | $26,332 |
| GlatopaGlatiramer Acetate | 13 | $25,377 |
| FarxigaDapagliflozin Propanediol | 71 | $25,163 |
| Divalproex Sodium | 506 | $24,447 |
| TrulicityDulaglutide | 38 | $23,647 |
| Gabapentin | 972 | $23,637 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $64 | $533,7151,429 claims |
| Johnson & JohnsonXarelto | $12 | $116,293273 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Incruse Ellipta | $104 | $85,110199 claims |
| MerckJanuvia | $13 | $80,281191 claims |
| AstraZenecaFarxiga, Brilinta | $166 | $36,514121 claims |
| NovartisEntresto | $82 | $33,96082 claims |
| Lilly USA, LLCTrulicity | $26 | $23,64738 claims |
| Astellas Pharma US IncMyrbetriq | $151 | $23,55864 claims |
| Novo NordiskOzempic | $36 | $22,02619 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $59,088 | $16,43821 claims |
| Sanofi-aventis U.S. LLCMultaq | $15 | $11,62514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Sicklerville
- David ShulkinMorristown$1.7M
- Howard UdermanLakewood$955K
- Darshi SunderamEast Orange$530K
- Annika DrongeEmerson$401K
- Stephen MarcellaNew Brunswick$331K
- Viju VijaysadanKinnelon$325K
- Mark MonaneWoodcliff Lake$268K
- Martin BedigianLivingston$240K
- Rameck HuntPlainsboro$217K
- Angel LazoSecaucus$195K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.